Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide dose-response in obese type 2 diabetes
NCT01511198Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2001
- Primary completion
- Oct 2001
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of liraglutide in type 2 diabetes mellitus (T2DM), obesity, sponsored by Novo Nordisk. Started Feb 2001; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT01511198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01511198.